Trials / Completed
CompletedNCT02702271
Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
Protection Against Embolism for Non-valvular AF Subjects: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 458 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a prospective, non-randomized, multi-center investigation to establish the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure Device for subjects with non-valvular atrial fibrillation who are eligible for long-term anti-coagulation therapy to reduce the risk of stroke but who have a rationale to seek a non-pharmacologic alternative.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | WATCHMAN FLX | Left atrial appendage closure with WATCHMAN FLX |
Timeline
- Start date
- 2018-05-07
- Primary completion
- 2020-01-28
- Completion
- 2021-03-12
- First posted
- 2016-03-08
- Last updated
- 2022-06-14
- Results posted
- 2022-06-14
Locations
29 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02702271. Inclusion in this directory is not an endorsement.